

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-173) TARLATAMAB

PRONUNCIATION tar lat' ue mab

THERAPEUTIC CLAIM Antineoplastic

## CHEMICAL NAMES

1. Immunoglobulin, anti-(human notch ligand DLL3) (human monoclonal daeld-hwzv-1 single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen  $\epsilon$ -chain) (human monoclonal daeld-hwzv-1 single-chain variable fragment VH2-(GGGGS)3-VL2) fusion protein with peptide linker (GGGG) fusion protein with immunoglobulin G1 (human  $\gamma$ 1-chain C-region C-terminal fragment) fusion protein with peptide linker (GGGGS)6 fusion protein with immunoglobulin G1 (human  $\gamma$ 1-chain C-region C-terminal fragment) (Source: CAS)
2. Immunoglobulin scFv-scFv-scFc, anti-[*Homo sapiens* DLL3 (delta-like ligand 3)] and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], monoclonal antibody single chain (scFv)<sub>2</sub>-scFc, bispecific; IG single chain scFv-scFv-scFc, anti-DLL3 and anti-CD3E (1-982) [scFv-VH-V-kappa anti-DLL3 (1-241) [VH (*Homo sapiens* IGHV4-59\*01 G49>C (44) (96.9%) -(IGHD) -IGHJ4\*01 (100%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-118) -15-mer-tris(tetraglycyl-seryl) linker (119-133) -V-KAPPA (*Homo sapiens* IGKV3-20\*01 (91.7%) -IGKJ2\*01 Q120>C (234) (90.9%)) CDR-IMGT [7.3.9] (160-166.184-186.223-231) (134-241)] -6-mer-seryl-tetraglycyl-seryl linker (242-247) -scFv-VH-V-lambda anti-CD3E (248-496) [VH (*Mus musculus* IGHV10-1\*02 (91.9%) -(IGHD) -IGHJ3\*01 (86.7%)/*Homo sapiens* IGHV3-73\*01 (87.0%) -(IGHD) -IGHJ5\*01 (100%)) CDR-IMGT [8.10.16] (273-280.298-307.346-361) (248-372)-15-mer-tris(tetraglycyl-seryl) linker (373-387) -V-LAMBDA (*Homo sapiens* IGLV7-43\*01 (85.1%) -IGLJ3\*02 (100%)) CDR-IMGT [9.3.9] (413-421.439-441.478-486) (388-496)] -4-mer-tetraglycyl linker (497-500) - scFc (h-CH2-CH3)-(h-CH2-CH3) (501-982) [*Homo sapiens* IGHG1\*03 h-CH2-CH3, nG1m1 (hinge 6-15 (501-510), CH2 R83>C (572), N84.4>G (577), V85>C (582) (511-620), CH3 E12 (636), M14 (638) (621-725), CHS>del) (501-725) -30-mer-hexakis(tetraglycyl-seryl) linker (726-755) -*Homo sapiens* IGHG1\*03 h-CH2-CH3, nG1m1 (hinge 6-15 (756-765), CH2 R83>C (827), N84.4>G (832), V85>C (837) (766-875), CH3 E12 (891), M14 (893) (876-980), CHS (981-982)) (756-982)]], produced in Chinese hamster ovary (CHO) cells, non-glycosylated (Source : WHO pINN list 123)

## STRUCTURAL FORMULA

### Sequence

QVQLQESGPG	LVKPSETLSL	TCTVSGGSIS	SYVSWIRQP	PGKCLEWIGY	50
VYYSGTNYN	PSLKSRTVIS	VDTSKNQFSL	KLSSVTAADT	AVYYCASIAV	100
TGFYFDYWQ	GTLVTVSSGG	GGSGGGGSGG	GGSEIVLTQS	PGTSLSPGE	150
RVTLSCRASQ	RVNNNYLAWY	QQRPGQAPRL	LIYGASSRAT	GIPDRFSGSG	200

SGTDFTLTIS	RLEPEDFAVY	YCQQYDRSPL	TFGCGTKLEI	KSGGGGSEVQ	250
LVESGGGLVQ	PGGSLKLSCA	ASGFTFNKYA	MNWVRQAPGK	GLEWVARIRS	300
KYNNYATYYA	DSVKDRFTIS	RDDSKNTAYL	QMNNLKTEDT	AVYYCVRHGN	350
FGNSYISYWA	YWQQTLLTVV	SSGGGSGGGG	GSGGGGSQTV	VTQEPSLTVS	400
PGGTVTLTCG	SSTGAVTSGN	YPNWVQKPG	QAPRGLIGGT	KFLAPGTPAR	450
FSGSLLGKKA	ALTLSGVQPE	DEAEYYCVLW	YSNRWVFGGG	TKLTVLGGGG	500
DKTHTCPCP	APELLGGPSV	FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	550
PEVKFNWYVD	GVEVHNAKTK	PCEEQYGSTY	RCVSVLTVLH	QDWLNGKEYK	600
CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	650
GFYPSDIAVE	WESNGQPENN	YKTTPPVLDS	DGSFFLYSKL	TVDKSRWQQG	700
NVFSCVMHE	ALHNHYTQKS	LSLSPGGGGS	GGGGSGGGGS	GGGGSGGGGS	750
GGGSDKTHT	CPPCPAPELL	GGPSVFLFPP	KPKDTLMISR	TPEVTCVVVD	800
VSHEDPEVKF	NWYVDGVEVH	NAKTKPCEEQ	YGSTYRCVSV	LTVLHQDWLN	850
GKEYKCKVSN	KALPAPIEKT	ISKAKGQPRE	PQVYTLPPSR	EEMTKNQVSL	900
TCLVKGFYPS	DIAVEWESNG	QFENNYKTPP	PVLDSGGSFF	LYSKLTVDKS	950

Disulfide bridges

22-95	44-234	156-222	269-345	409-477	506-761	509-764	541-601
572-582	647-705	796-856	827-837	902-960			

MOLECULAR FORMULA  $C_{4664}H_{7139}N_{1259}O_{1454}S_{34}$  (firm)

MOLECULAR WEIGHT 105.1 kDa

TRADEMARK None as yet

SPONSOR Amgen Inc.

CODE DESIGNATIONS AMG 757

CAS REGISTRY NUMBER 2307488-83-9

UNII 74X82ST8Q1

WHO NUMBER 11420

gbk